The first validated peptide specific inhibitor against the catalytic activity of NSD2 in multiple myeloma cases was PTD2 [121], whose inhibitor effect is specific in the presence of the cofactor S-adenosyl-L-methionine (SAM). This evidence concerns the gene NSD2 and plasma cell myeloma.